Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Argentine Healthy Population
NCT04560881Phase 3Completed
- Sponsor
- Laboratorio Elea Phoenix S.A.
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Covilo with Placebo (2 arms). Primary endpoint: Incidence of COVID-19 cases after two-doses of vaccination. Started Sep 2020; status: completed.
02
Drugs
BBIBP-CorV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04560881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04560881.